Jornay Pm Patent Expiration

Jornay Pm is a drug owned by Ironshore Pharmaceuticals And Development Inc. It is protected by 16 US drug patents filed from 2018 to 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 23, 2032. Details of Jornay Pm's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9603809 Methods of treatment of attention deficit hyperactivity disorder
Mar, 2032

(7 years from now)

Active
US9028868 Methods and compositions for treatment of attention deficit disorder
Mar, 2032

(7 years from now)

Active
US9034902 Methods for treatment of attention deficit hyperactivity disorder
Mar, 2032

(7 years from now)

Active
US8916588 Methods for treatment of attention deficit hyperactivity disorder
Mar, 2032

(7 years from now)

Active
US11241391 Compositions for treatment of attention deficit hyperactivity disorder
Mar, 2032

(7 years from now)

Active
US10292937 Methods of treatment of attention deficit hyperactivity disorder
Mar, 2032

(7 years from now)

Active
US10617651 Compositions for treatment of attention deficit hyperactivity disorder
Mar, 2032

(7 years from now)

Active
US10881618 Compositions for treatment of attention deficit hyperactivity disorder
Mar, 2032

(7 years from now)

Active
US11911518 Compositions for treatment of attention deficit hyperactivity disorder
Mar, 2032

(7 years from now)

Active
US11241392 Compositions for treatment of attention deficit hyperactivity disorder
Mar, 2032

(7 years from now)

Active
US10182995 Compositions for treatment of attention deficit hyperactivity disorder
Mar, 2032

(7 years from now)

Active
US8927010 Compositions for treatment of attention deficit hyperactivity disorder
Mar, 2032

(7 years from now)

Active
US9023389 Compositions for treatment of attention deficit hyperactivity disorder
Mar, 2032

(7 years from now)

Active
US10905652 Compositions for treatment of attention deficit hyperactivity disorder
Mar, 2032

(7 years from now)

Active
US9498447 Compositions for treatment of attention deficit hyperactivity disorder
Mar, 2032

(7 years from now)

Active
US9283214 Compositions for treatment of attention deficit hyperactivity disorder
Mar, 2032

(7 years from now)

Active


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Jornay Pm's patents.

Given below is the list of recent legal activities going on the following patents of Jornay Pm.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 4th Yr, Small Entity 17 Jul, 2024 US10905652
Payment of Maintenance Fee, 4th Yr, Small Entity 19 Jun, 2024 US10881618
Email Notification 08 May, 2024 US11911518
Payment of Maintenance Fee, 8th Yr, Small Entity 08 May, 2024 US9498447
Patent eCofC Notification 07 May, 2024 US11911518
Recordation of Patent eCertificate of Correction 07 May, 2024 US11911518
Mail Patent eCofC Notification 07 May, 2024 US11911518
Email Notification 07 May, 2024 US11911518
Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 20 Mar, 2024 US10881618
Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 20 Mar, 2024 US11241392


FDA has granted several exclusivities to Jornay Pm. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Jornay Pm, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Jornay Pm.

Exclusivity Information

Jornay Pm holds 1 exclusivities. All of its exclusivities have expired in 2021. Details of Jornay Pm's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Aug 08, 2021

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Jornay Pm is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Jornay Pm's family patents as well as insights into ongoing legal events on those patents.

Jornay Pm's Family Patents

Jornay Pm has patent protection in a total of 14 countries. It's US patent count contributes only to 49.1% of its total global patent coverage. Click below to unlock the full patent family tree for Jornay Pm.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Jornay Pm's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Mar 23, 2032 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Jornay Pm Generics:

Methylphenidate Hydrochloride is the generic name for the brand Jornay Pm. 42 different companies have already filed for the generic of Jornay Pm, with Specgx Llc having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Jornay Pm's generic

Alternative Brands for Jornay Pm

Jornay Pm which is used for treating Attention Deficit Hyperactivity Disorder (ADHD)., has several other brand drugs in the same treatment category and using the same active ingredient (Methylphenidate Hydrochloride). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name Treatment Area
Purdue Pharma Lp
Adhansia Xr

(uses Methylphenidate Hydrochloride)

Used for managing symptoms of Attention Deficit Hyperactivity Disorder (ADHD).
Rhodes Pharms
Aptensio Xr

(uses Methylphenidate Hydrochloride)

Used for managing Attention Deficit Hyperactivity Disorder (ADHD).

Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Methylphenidate Hydrochloride. Given below is the list of those drugs and companies owning them.

Drug Owner Drug Name
Aytu Biopharma
Metadate Cd
Commave Therap
Azstarys
Janssen Pharms
Concerta
Nextwave
Quillivant Xr
Nextwave Pharms
Quillichew Er
Sandoz
Focalin
Focalin Xr
Ritalin La
Specgx Llc
Methylin


Apart from brand drugs containing the same ingredient, some generics have also been filed for Methylphenidate Hydrochloride, Jornay Pm's active ingredient. Check the complete list of approved generic manufacturers for Jornay Pm





About Jornay Pm

Jornay Pm is a drug owned by Ironshore Pharmaceuticals And Development Inc. It is used for treating Attention Deficit Hyperactivity Disorder (ADHD). Jornay Pm uses Methylphenidate Hydrochloride as an active ingredient. Jornay Pm was launched by Ironshore Pharms in 2018.

Approval Date:

Jornay Pm was approved by FDA for market use on 08 August, 2018.

Active Ingredient:

Jornay Pm uses Methylphenidate Hydrochloride as the active ingredient. Check out other Drugs and Companies using Methylphenidate Hydrochloride ingredient

Treatment:

Jornay Pm is used for treating Attention Deficit Hyperactivity Disorder (ADHD).

Dosage:

Jornay Pm is available in capsule, extended release form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
20MG CAPSULE, EXTENDED RELEASE Prescription ORAL
40MG CAPSULE, EXTENDED RELEASE Prescription ORAL
80MG CAPSULE, EXTENDED RELEASE Prescription ORAL
100MG CAPSULE, EXTENDED RELEASE Prescription ORAL
60MG CAPSULE, EXTENDED RELEASE Prescription ORAL